← Eichor
Condition: Hemostatic Disorder Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Hemostatic Disorder

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Long-term Extension Study of PCI-32765 (Ibrutinib)
Phase 3 · 175 location(s) · Janssen Research & Development, LLC · NCT01804686Activity Levels in Bone Marrow Transplant Patients
Phase N/A · 1 location(s) · Michael Tomasson · NCT04115241Severe Congenital Hemostatic Defects, Cerebral MIcrobleeds and COGnition
Phase N/A · 1 location(s) · University Hospital, Lille · NCT06090201Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
Phase 2 · 1 location(s) · University of Rochester · NCT05597345A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
EARLY_Phase 1 · 1 location(s) · Shanghai Cell Therapy Group Co.,Ltd · NCT06732232Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)
Phase 1 · 5 location(s) · Chongqing Peg-Bio Biopharm Co., Ltd. · NCT06880081A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomi
Phase 2 · 16 location(s) · Karyopharm Therapeutics Inc · NCT04414475A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or R
Phase 3 · 1 location(s) · Genrix (Shanghai) Biopharmaceutical Co., Ltd. · NCT07452198The Severe Von Willebrand Disease (sVWD) Patient Registry
Phase N/A · 1 location(s) · VWD Connect Foundation · NCT05437536AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Phase 1 · 13 location(s) · Carna Biosciences, Inc. · NCT05602363A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Pr
Phase 4 · 2 location(s) · Sanofi · NCT06145373Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone
Phase 3 · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06561854Clinical and Basic Investigations Into Hermansky-Pudlak Syndrome
Phase N/A · 1 location(s) · National Human Genome Research Institute (NHGRI) · NCT00001456Methods of T Cell Depletion Trial (MoTD)
Phase 2 · 17 location(s) · University of Birmingham · NCT04888741An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treatin
EARLY_Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT07101705Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma
Phase N/A · 1 location(s) · The Royal Wolverhampton Hospitals NHS Trust · NCT04234022Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma
Phase 2 · 1 location(s) · Stanford University · NCT06461988Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05776979Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
Phase 2 · 29 location(s) · European Myeloma Network B.V. · NCT07107529Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults
Phase 4 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT04518475Romiplostim for Oral TPO-RA Resistant ITP
NA · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07612319All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06158412Discontinuation Study
NA · 1 location(s) · University College Cork · NCT05866757V-IMMUNE® for Immune Thrombocytopenia
Phase 3 · 2 location(s) · On Pharma Importadora, Exportadora e Distribuidora de Medica · NCT06962631Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-
Phase 2 · 1 location(s) · Carl Ola Landgren, MD, PhD · NCT06100237A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07454382In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT07239323A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT05214391Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia
Phase N/A · 7 location(s) · Carevive Systems, Inc. · NCT05974150Endothelial Colony-Forming Cells in Patients With VWD, AVWS and Healthy Subjects
Phase N/A · 1 location(s) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · NCT07358013
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.